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16S rRNA Based Polymerase Chain Reaction Compared with 
Culture and Serological Methods for Diagnosis of 
Mycoplasma pneumoniae Infection
F.J. van Kuppeveld1*, K.-E. Johansson2, J.M. Galama1, J. Kissing1, G. Bölske2, E. Hjelm3, 
J.T. van der Logt1, W.J. Melchers1
The use of a 16S rRNA based polymerase chain reaction (PCR) for the detection of 
Mycoplasma pneumoniae infection was investigated. Sputum samples from 34 
patients with respiratory illness and evidence of pneumonia as judged by chest X-ray 
were analyzed by PCR and microbiological culture. Throat swabs from 14 healthy in­
dividuals were used as controls. For serology, an enzyme immunoassay for the detec­
tion of immunoglobulin M antibodies and a complement fixation assay were per­
formed. Evidence of Mycoplasma pneumoniae infection was obtained in ten patients 
(29 %), eight of whom were found positive by both PCR and serology. Two of the 
sputum samples from these eight patients were negative by culture. Of the remaining 
two patients positive for Mycoplasma pneumoniae, one was positive by PCR and cul­
ture but negative by serology, and one was found positive by serology but negative by 
PCR and culture. Thirteen of the 14 controls were negative by both PCR and serology. 
One control, however, was negative by serology but positive by PCR, which was prob­
ably due to asymptomatic carriage of Mycoplasma pneumoniae. The results of this 
study indicate the suitability of the PCR for the detection of Mycoplasma pneumoniae 
in clinical samples as well as its potential value as an additional tool for the diagnosis of 
infection.
Mycoplasma pneumoniae is a human pathogen 
that primarily causes respiratory infections. Al­
though most of these infections are mild (1), 
severe bronchopneumonia and lung abscesses can 
occur (2). Furthermore, extrapulmonary compli­
cations such as meningitis, neuritis, myocarditis, 
pericarditis, and erythema multiforme have been 
reported, sometimes with a fatal outcome (3). A 
rapid and sensitive routine laboratory test is re­
quired for accurate diagnosis and adequate treat­
ment of Mycoplasma pneumoniae infections.
The diagnostic methods currently used rely 
mainly on in vitro isolation of Mycoplasma pneu­
moniae and on serology. Culture is relatively time 
consuming, requires specialised media, and may
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be difficult to accomplish because of the fast­
idious nature of Mycoplasma pneumoniae. For 
serological diagnosis of Mycoplasma pneumoniae 
infection, several methods are available, but all of 
them have shortcomings. The cold agglutinin test 
is both nonspecific and insensitive (4,5). The com­
plement fixation assay (CFA) is not entirely 
specific and requires paired sera to demonstrate a 
rise in antibody titre (6). Paired sera are also re­
quired for the microparticle agglutination assay 
(7). Finally, immunoglobulin M (IgM) antibodies 
as detected by enzyme immunoassay (EIA) may 
be absent in reinfections (6,8).
Techniques to demonstrate genomic sequences 
have been proposed as rapid and specific alterna­
tives. Although hybridisation with DNA probes 
has been proven to be highly specific, low levels of 
Mycoplasma pneumoniae cannot be detected (9, 
10,11). The use of the polymerase chain reaction 
(PCR) for the detection of Mycoplasma pneu­
moniae has been tested in experimentally infected 
animals (12), in simulated clinical samples (13,14), 
and recently also in clinical samples (15-18).
402 Eur. J. Clin. Microbiol. Infect. Dis.
We have developed a PCR assay with primers 
selected from variable regions of 16S rRNA to 
detect my coplasmas at both the genus and species 
level (19, 20). This PCR assay has been used for 
the detection of experimental Mycoplasma pul­
monis infection in rats (21), Mycoplasma hominis 
associated with a case of stillbirth (22) and myco­
plasma contamination in cell cultures (23). In the 
present report, we describe the application of a 
Mycoplasma pneumoniae-specific 16S rRNA 
based PCR assay (19) for the detection of Myco­
plasma pneumoniae infection. The value of this 
PCR assay was investigated by comparing the re­
sults with those obtained by microbiological cul­
ture and serology.
G C C ATT A CCT G CFA A -3 ’ ) w ere used, which resulted 
in an amplification product of 277 bp (19). The probe 
GPO-1 (5’-CrCTAGCCATTACCTGCTAA-3’) was used 
for Southern blot hybridisation (19). The therm al profile 
involved 40 cycles of dénaturation at. 94 °C fo r 1 min, 
prim er annealing a t 60 °C for 1 min, and prim er extension 
at 72 °C for 2 min.
Serological M ethods. A n IgM -EIA  (M P Test IgM , D ia- 
tech Diagnostica, Israel) was used according to  th e  m an­
ufacturer's recom m endations. In addition, a CFA with 
commercially available M ycoplasm a pneum oniae  antigen 
(Behring, G erm any) was perform ed. Serology was re ­
garded as positive if the serum  was found positive in the 
IgM -EIA  and/or when at least a four-fold increase in 
antibody titre  was found in paired sera tested in the CFA. 
In all o ther cases serology was regarded as negative.
M aterials and Methods
Patients and Clinical Samples. Clinical specimens were 
collected from 34 patients adm itted to the D epartm ent 
o f Infectious D iseases of the U niversity H ospital in U p­
psala. All patients suffered from  respiratory illness and 
showed evidence of pneum onia by X-ray. Sputum  and 
serum  sam ples w ere collected about one week after the 
onset o f symptoms. C onvalescent phase sera w ere col­
lected from  seven patiente w ithin one to  six weeks. C ul­
tu re  of M ycoplasm a pneum oniae  was perform ed both at 
the D epartm en t of Infectious Diseases of the University 
H ospital in U ppsala and a t the N ational V eterinary In­
stitute. F or PC R  analysis, the sputum  sam ples were 
frozen, lyophilized, coded and sent to  the D epartm ent 
of M edical M icrobiology of the U niversity of Nijmegen. 
Serological investigations were perform ed at the D epart­
m ent of Clinical M icrobiology of the University H ospital 
in U ppsala. As controls, th roat swabs and sera from  14 
individuals w ithout respiratory  illness were tested.
M icrobiological Culture. A t the D epartm ent of Clinical 
M icrobiology of the University H ospital in U ppsala, cul­
tu re  of M ycoplasm a pneum oniae  was perform ed accord­
ing to standard procedures with SP4 bro th  and PPLO 
agar (24). A t the N ational V eterinary Institu te, culture 
was perform ed with the F medium , as described by Bölske 
(25). M ycoplasma isolates w ere identified by the indirect 
im m unofluorescence test of unfixed colonies (26). The 
sam ples w ere scored positive in culture if they were found 
positive by e ither of the tw o methods.
Polymerase Chain Reaction. Lyophilized sputum  samples 
were resuspended in w ater in their original volume. 
T hroat swabs w ere suspended in 1 ml of phosphate- 
buffered saline solution, centrifuged for 10 min at 
10,000 x g, and resuspended in 200 |il of water. Nucleic 
acids were isolated from 200 |il of sputum  or th roat swab 
sam ple and lesnspended  in 50 p.1 oí water. F o r PC R  analy­
sis, 10 nl o f the nucleic acid solution was used. Isolation 
of nucleic acid, am plification by the PCR, and analysis 
of the am plified samples w ere perform ed as described 
previously (22). In the PCR, the M ycoplasma pneu- 
m owae-specific primers (forward primer, 5’-A A G G A - 
C CTG CA A G G G TTCG T-3’; reverse primer, 5’-CTCTA-
Results
The results for both the patients and the control 
group are shown in Table 1. Evidence of Myco­
plasma pneumoniae infection by culture, PCR or 
serology was found in ten of the 34 (29 %) 
patients with respiratory illness. The remaining 
24 patients were negative by culture, PCR and 
IgM-EIA and had no detectable CF antibodies 
(data not shown). Of the 14 healthy individuals, 
13 were negative by both PCR and serology, 
whereas one person was negative by serology but 
positive by PCR.
More detailed information about the ten patients 
positive for Mycoplasma pneumoniae is pre­
sented in Table 2. Convalescent phase sera were
Table 1: D etection of Mycoplasma pneum oniae  infection 
by culture, PCR and serological methods in 34 patients with 
clinical signs of pneumonia and positive X-ray and in 14 
healthy controls,




Patients 24 _ _ _
(n = 34) 6 + + +
1 ±* + +
1 - + 4*
1 + + _
1 - - +
H ealthy controls 13 N D _ _
(n =  14) 1 ND + -
* R eported as suspected but unconfirmed positive by cul­
ture. Strain was lost at subculture before unequivocal 
identification could be achieved.
ND: not done.
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Table 2: Comparison of the results of serological methods (IgM -EIA and complement fixation assay), 








E IA CFA titre
1 M 19 acute + 1:15 ±a +







3 M 42 acute + 1:60 + +
4 M 24 acute + 1:15 - +
5 M 19 acute + <1:7.5 + +
6 F 16 acute





7 M 30 acute + 1:60 + +








9 M 42 acute + 1:60 + +
10 M 33 acute - 1:15 + +
a R eported as suspected but unconfirmed positive by culture. Strain was lost at subculture before 
unequivocal identification could be achieved, 
b N um ber of days between collection of acute and convalescent phase sera is given in parentheses. 
CFA = complement fixation assay.
available from only three of these patients. The 
CF titres obtained with the acute phase sera from 
the seven remaining patients are also shown, be­
cause high CF antibody titres are suggestive for 
recent infection. Of the eight patients positive by 
both serology and PCR, two were negative by cul­
ture. One other patient (patient no. 10) was posi­
tive by culture and PCR, but negative by serology. 
In total, culture of Mycoplasma pneumoniae was 
clearly positive in seven of the nine sputum 
samples (78 %) that were positive by PCR. For 
patient no. 6, both PCR and culture were nega­
tive, but serology was positive.
Discussion
In this study, the suitability of a 16S rRNA based 
PCR assay for the detection of Mycoplasma pneu­
moniae infection was investigated by comparison 
of the PCR results with those obtained by culture
and serology. Evidence of Mycoplasma pneu­
moniae infection was found in ten of the 34 
patients with respiratory illness. Mycoplasma 
pneumoniae was detected in sputa from nine 
patients by PCR. In seven of these nine patients, 
Mycoplasma pneumoniae could be cultured from 
sputa. The two patients who were negative in cul­
ture were, however, positive by serology, which 
indicates that these patients were indeed suffer­
ing from an acute infection. Culture of sputum 
from one of these two patients was suspected to 
be positive for Mycoplasma pneumoniae, but this 
could not be confirmed by typing because the iso­
late was lost upon subculture. Problems in cultur­
ing Mycoplasma pneumoniae have been reported 
by several authors. For instance, Skakni et al. (17) 
isolated Mycoplasma pneumoniae from only one 
of the 20 throat samples that were positive by 
PCR. Lüneberg et al. (16) detected Mycoplasma 
pneumoniae by PCR in 14 culture-negative throat 
swabs from serologically positive patients. In con­
trast to these findings, Kai et al. (15) detected My­
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coplasma pneumoniae by PCR in only 22 of the 30 
throat swabs that were positive by culture. In that 
particular study, however, culture was regarded as 
positive when a change in colour of the medium 
was observed and the growth of Mycoplasma 
pneumoniae was not confirmed. Therefore, the 
authors themselves state that their culture 
method may not have been specific for Myco­
plasma pneumoniae.
The results of PCR and serology were in agree­
ment for eight patients. Discrepancies between 
the results of PCR and serology were observed 
for two patients and one healthy control. Patient 
no. 10 was positive by PCR but negative by 
serology. Since culture was also positive for this 
patient, a false-positive PCR result due to DNA 
carry-over contamination seems very unlikely. 
The absence of a distinct IgM response might be 
due to a reinfection. Alternatively, the serum 
could have been collected too soon after the onset 
of symptoms to detect IgM antibodies. Unfor­
tunately, no convalescent phase serum was availa­
ble from this patient, which made demonstration 
of a rise in CFA titre impossible. The detection of 
Mycoplasma pneumoniae in the absence of an 
IgM response could also be due to persistence of 
the organism in the respiratory tract following a 
previous infection. Although this patient suffered 
from respiratory illness and showed evidence of 
pneumonia by X-ray, Mycoplasma pneumoniae 
may not have been the causative agent. Skakni et 
al. (17) and Williamson et al. (18) described the 
detection of Mycoplasma pneumoniae by PCR in 
patients without serological evidence of infection 
and in patients with a previous infection and con­
cluded that Mycoplasma pneumoniae can pro­
duce persistent and asymptomatic infections. A 
persistent or asymptomatic carriage of Myco­
plasma pneumoniae was also observed in this 
study in one of the controls who was positive by 
PCR but showed no clinical signs or serological 
evidence of infection.
A  disagreement between the results of PCR and 
serology was also observed in patient no. 6, who 
was negative by PCR and culture but positive by 
serology. Several possible explanations can be 
given for this discrepancy. The number of or­
ganisms in this sputum sample may have been 
below the detection limit of the PCR. Alterna­
tively, Mycoplasma pneumoniae may already 
have been eradicated before the sputum sample 
was taken. The serological data indicate that this 
patient was no longer in the acute phase of the 
disease; a high CF antibody titre was already de­
tectable in the first serum sample, and serum
taken one week after the first sample was nega­
tive in the IgM-EIA. Therefore, the sputum 
sample, which was collected on the same day as 
the first serum sample, may have been collected 
at a timepoint at which it was no longer possible 
to detect Mycoplasma pneumoniae. It is unlikely 
that Mycoplasma pneumoniae was eradicated by 
antibiotics, since the sputum sample was collected 
only one day after this patient had received ery­
thromycin.
In conclusion, the results of this study demon­
strate that culture is not always sensitive enough 
to detect Mycoplasma pneumoniae. Further­
more, culture is not rapid enough, since several 
weeks were sometimes required for isolation of 
Mycoplasma pneumoniae. The 16S rRNA based 
PCR described here is suitable for the detection 
of Mycoplasma pneumoniae in clinical samples. 
Thus, the PCR procedure could well replace cul­
ture and become the method of choice for the de­
tection of Mycoplasma pneumoniae in clinical 
samples. Because it has been demonstrated that 
the detection of Mycoplasma pneumoniae in the 
respiratory tract does not necessarily correlate 
with respiratory disease, serological tests should 
be used in addition to the PCR to distinguish be­
tween acute and persistent infections. The PCR 
may be especially valuable for the detection of 
Mycoplasma pneumoniae in immunocom­
promised patients, as was already demonstrated 
by Skakni et al. (17), and for the detection of My­
coplasma pneumoniae in organs and tissues of 
patients with extrapulmonary complications to 
address the role of Mycoplasma pneumoniae in 
these nonrespiratory disease states.
Acknowledgements
We thank Elisabeth W ilhelmsson and M arianne Persson 
for skillful technical assistance and the staff a t the D e­
partm ent of Infectious D iseases o f the U niversity H ospi­
tal in U ppsala for collecting the specimens. This w ork 
was supported financially by grants from  th e  Swedish 
Council for Forestry and A gricultural R esearch.
References
1. Foy HM, Cooney MK, McMahan R, Grayston JT:
Viral and mycoplasmal pneum onia in a prepaid m edi­
cal care group during an eight-year period. American 
Journal of Epidemiology 1973, 97: 93-102.
2. Siegler DIM: Lung abscess associated with M yco­
plasma pneumoniae infection. British Journal of D is­
eases of the Chest 1973, 67: 123.
Vol. 13,1994 405
3. Couch RB: Mycoplasma pneum oniae  (primary atypical 
pneum onia). In: M andell GL, Douglas R G  Jr, Bennett 
JE  (ed): Principles and practice of infectious diseases. 
Churchill Livingstone, New York, 1990, p. 1446-1458.
4. Clyde WA Jr: Mycoplasma pneumoniae respiratory 
disease symposium: sum mation and significance. Yale 
Journal of Biology and Medicine 1983, 56: 523-527.
5. Murray HW, Masur H, Sentcrfit LB, Roberts RB: The 
protean manifestations of Mycoplasma pneum oniae in­
fection in adults. American Journal of Medicine 1975, 
58: 229-242.
6. Sillis M: The limitations of IgM assay in the serological 
diagnosis of M ycoplasma pneumoniae infections. Jour­
nal of Medical Microbiology 1990, 33: 253-258.
7. Echevarria JM, Leon P, Balafagon P, Lopez JA, Fer­
nandez MV: Diagnosis of Mycoplasma pneumoniae in­
fection by microparticle agglutination and immuno- 
capture enzyme-immunoassay. European Journal of 
Clinical Microbiology and Infectious Diseases 1990, 
9: 217-220.
8. van Griethuysen A JA , de Graaf R, van Drouten JAM, 
Heessen FWA, van der Logt JTM, van Loon AM:
U se of enzyme-linked im m unosorbent assay for the 
early diagnosis of Mycoplasma pneum oniae infection. 
European Journal of Clinical Microbiology 1984, 3: 
116-121.
9. Göbel U B, Geiser A , Stanbridge EJ: Oligonucleotide 
probes complementary to  variable regions of ribo- 
somal R N A  discriminate betw een Mycoplasma spe­
cies. Journal of G eneral Microbiology 1987,133:1969­
1974.
10. Hyman HC, Yogev D , Razin S: D N A  probes for de­
tection and identification of Mycoplasma pneumoniae 
and M ycoplasma genitalium. Journal of Clinical Mi­
crobiology 1987, 25: 726-728.
11. Tilton RC, Dias F, Kidd H, Ryan RW: D N A  probe 
versus culture for detection of Mycoplasma pneu- 
moniae in clinical specimens. Diagnostic Microbiology 
and Infectious Disease 1988, 10: 109-112.
12. Bernet C, Garret M, de Barbeyrac B, Bebear C, Bon­
net J: D etection of Mycoplasma pneum oniae by using 
the polymerase chain reaction. Journal of Clinical Mi­
crobiology 1989, 27: 2492-2496.
13. Buck GE, O’Hara LC, Summersgill J: Rapid, sensitive 
detection of M ycoplasma pneumoniae in simulated 
clinical specimens by D N A  amplification. Journal of 
Clinical Microbiology 1992, 30: 3280-3283.
14. Skov Jensen J, Sondergárd-Andersen J, Uldum SA, 
Lind K: D etection of Mycoplasma pneumoniae in 
simulated clinical samples by polymerase chain reac­
tion. A cta Pathologica et Microbiologica et Immuno- 
logica Scandinavica 1989, 97: 1046-1048.
15. Kai M, Kainiya S, Yabe H, Takakura I, Shiozawa K, 
Ozawa A: Rapid detection of Mycoplasma pneu­
m oniae in clinical samples by the polymerase chain 
reaction. Journal of Medical Microbiology 1993, 38: 
166-170.
16. Liineberg E, Skov Jensen J, Frosch M: D etection of 
Mycoplasma pneumoniae by polym erase chain reac­
tion and nonradioactive hybridization in m icrotiter 
plates. Journal of Clinical Microbiology 1993,31:1088­
1094.
17. Skakni L, Sardet A , Just J, Landman-Parker J, Costil 
J, Moniot-Ville N, Bricout F, Garbarg-Chenon A: D e­
tection of Mycoplasma pneum oniae in clinical samples 
from pediatric patients by polym erase chain reaction. 
Journal of Clinical Microbiology 1992, 30: 2638-2643.
18. Williamson J, Marmion BP, Worswick D A , Kok TW, 
Tannock G, Herd R, Harris RJ: Laboratory diagnosis 
of Mycoplasma pneumoniae infection. Antigen capture 
and PCR-gene amplification for detection of the my­
coplasma: problems of clinical correlation. Epidem i­
ology and Infection 1992, 109: 519-537.
19. van Kuppeveld FJM, van der Logt JTM, Angulo AF, 
van Zoest MJ, Quint WGV, Niesters HGM, Galama 
JMD, Melchers WJG: Genus- and species- specific 
identification of mycoplasmas by 16S rR N A  amplifi­
cation. Applied and Environm ental Microbiology
1992, 58: 2606-2615.
20. van Kuppeveld FJM, van der Logt JTM, Angulo AF, 
van Zoest MJ, Quint WGV, Niesters HGM, Galama 
JMD, Melchers WJG: Genus- and species-specific 
identification of mycoplasmas by 16S rR N A  amplifi­
cation. Applied and Environm ental Microbiology
1993, 59: 655.
21. van Kuppeveld FJM, Melchers WJG, Willemse HFM, 
Kissing J, Galama JMD, van der Logt JTM: D etection 
of Mycoplasma pulm onis in experimentally infected 
laboratory rats by 16S rR N A  amplification. Journal 
of Clinical Microbiology 1993, 31: 524-527.
22. Meis JM, van Kuppeveld FJM, Kremer JA , Nijhuis 
JG, Melchers WJG: Fatal intrauterine infection as­
sociated with M. hominis. Clinical Infectious Diseases 
1992, 15: 753-754.
23. van Kuppeveld FJM, Johansson K-E, Galama JMD, 
Kissing J, Bölske G, van der Logt JTM, Melchers 
WJG: D etection of mycoplasma contam ination in cell 
cultures by a mycoplasma group-specific PCR. Applied 
and Environm ental Microbiology 1994, 60: 149-152.
24. M I y  JG, Rose DL, Whitcomb RF, Wenzel RP: E n­
hanced isolation of M ycoplasma pneum oniae  from 
throat washings with a newly modified culture me­
dium. Journal of Infectious Diseases 1979, 139: 478­
482.
25. Bölske G: Survey of mycoplasma infections in cell cul­
tures and a comparison of detection methods. Z en­
tralblatt für Bakteriologie, Mikrobiologie und Hygiene 
(A) 1988, 269: 331-340.
26. Rosendal S, Black FT: D irect and indirect im m uno­
fluorescence of unfixed and fixed colonies. A cta Patho­
logica et Microbiologica Scandinavica 1972, 80: 615— 
622.
